4.8 Article

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer

期刊

SCIENCE TRANSLATIONAL MEDICINE
卷 14, 期 660, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.abj1531

关键词

-

资金

  1. NIH [R01NS112266, R35NS105076]
  2. HMS Blavatnik Award
  3. Austrian Federal Ministry of Education, Science and Research
  4. Austrian Academy of Sciences
  5. City of Vienna
  6. Austrian Science Fund (FWF) Wittgenstein award [Z 271-B19]
  7. T. von Zastrow foundation
  8. Canada 150 Research Chairs Program [F18-01336]
  9. CIHR [FRN 168899]
  10. HSCI Therapeutic Screening Center (TSC) grant [CF-0009-17-03]
  11. National Key R&D Program of China [2021YFE0193400]

向作者/读者索取更多资源

This study revealed that EGFR/KRAS signaling triggers increased expression of Gch1, contributing to pain perception. Inhibiting EGFR reduces GCH1 and BH4 expression and exerts analgesic effects. Additionally, GCH1/BH4 acts downstream of KRAS to drive lung cancer. These findings suggest that pharmacological modulation of GCH1 and BH4 expression could be a potential therapeutic strategy for pain management.
Increased tetrahydrobiopterin (BH4) generated in injured sensory neurons contributes to increased pain sensitivity and its persistence. GTP cyclohydrolase 1 (GCH1) is the rate-limiting enzyme in the de novo BH4 synthetic pathway, and human single-nucleotide polymorphism studies, together with mouse genetic modeling, have demonstrated that decreased GCH1 leads to both reduced BH4 and pain. However, little is known about the regulation of Gch1 expression upon nerve injury and whether this could be modulated as an analgesic therapeutic intervention. We performed a phenotypic screen using about 1000 bioactive compounds, many of which are target-annotated FDA-approved drugs, for their effect on regulating Gch1 expression in rodent injured dorsal root ganglion neurons. From this approach, we uncovered relevant pathways that regulate Gch1 expression in sensory neurons. We report that EGFR/KRAS signaling triggers increased Gch1 expression and contributes to neuropathic pain; conversely, inhibiting EGFR suppressed GCH1 and BH4 and exerted analgesic effects, suggesting a molecular link between EGFR/KRAS and pain perception. We also show that GCH1/BH4 acts downstream of KRAS to drive lung cancer, identifying a potentially druggable pathway. Our screen shows that pharmacologic modulation of GCH1 expression and BH4 could be used to develop pharmacological treatments to alleviate pain and identified a critical role for EGFR-regulated GCH1/BH4 expression in neuropathic pain and cancer in rodents.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据